IGF Oncology, LLC
IGF Oncology is dedicated to developing novel cancer drugs with better efficacy and lower side effects than existing chemotherapy options. Their lead drug, IGF-MTX, has shown promising results in clinical trials, including high effectiveness at lower doses and minimal side effects. The company focuses on targeted cancer therapies leveraging the insulin-like growth factor (IGF) pathway, with a strong emphasis on precision targeting of cancer cells to reduce harm to healthy tissue.
Industries
Nr. of Employees
small (1-50)
IGF Oncology, LLC
429 Birchwood Courts Birchwood, MN 55110 US
Patents
Insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome
US-11324834-B2
View DetailsFusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
US-10967049-B2
View DetailsFusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
US-10391147-B2
View DetailsFusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
US-9801923-B2
View DetailsFusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
US-9675671-B2
View Details
Insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome
US-11324834-B2
View DetailsFusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
US-10967049-B2
View DetailsFusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
US-10391147-B2
View DetailsFusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
US-9801923-B2
View DetailsFusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
US-9675671-B2
View DetailsProducts
Methotrexate–IGF receptor‑targeting conjugate
A chemically conjugated therapeutic in which a cytotoxic antifolate is linked to an engineered growth‑factor ligand to selectively deliver the drug to tumor cells that overexpress the cognate receptor; developed for advanced solid tumors and myelodysplastic syndrome (MDS).
Methotrexate–IGF receptor‑targeting conjugate
A chemically conjugated therapeutic in which a cytotoxic antifolate is linked to an engineered growth‑factor ligand to selectively deliver the drug to tumor cells that overexpress the cognate receptor; developed for advanced solid tumors and myelodysplastic syndrome (MDS).
Expertise Areas
- Targeted oncology drug development
- Receptor-mediated drug delivery
- Preclinical in vivo pharmacology
- Early‑phase clinical trial management
Key Technologies
- Drug–ligand conjugation chemistry
- Receptor-mediated targeted delivery
- In vivo murine tumor models
- Early‑phase clinical trials (Phase I/1b/2)
News & Updates
IGF Oncology is developing targeted cancer therapies, with promising clinical trial results for IGF-MTX, showing high efficacy at lower doses and minimal side effects.
IGF Oncology is developing targeted cancer therapies, with promising clinical trial results for IGF-MTX, showing high efficacy at lower doses and minimal side effects.